1 2 3
SUBSCRIBING TO COVER NOTE Case No. 19-cv-02945-PJH 8 B1526MACAR1800089,
9 Plaintiff, ORDER GRANTING MOTION FOR LEAVE TO AMEND; DENYING 10 v. WITHOUT PREJUDICE MOTION TO DISMISS; AND DENYING MOTION 11 ABAXIS, INC., et al., FOR LEAVE TO RESPOND 12 Defendants. Re: Dkt. Nos. 67, 68, 75
14 15 Before the court is defendants Abaxis, Inc. (“Abaxis”) and Zoetis, Inc.’s (“Zoetis” 16 and together with Abaxis, “defendants”) motion for leave to file a second amended 17 answer and crossclaim. Also before the court are cross-defendant C.H. Robinson 18 Worldwide, Inc.’s (“CHR” or “cross-defendant”) motion to dismiss and plaintiff 19 Underwriters at Lloyd’s Subscribing to Cover Note B1526MACAR1800089’s 20 (“Underwriters” or “plaintiff”) motion for leave to respond. The matters are fully briefed 21 and suitable for decision without oral argument. Having read the parties’ papers and 22 carefully considered their arguments and the relevant legal authority, and good cause 23 appearing, the court hereby rules as follows. 25 The complaint in this action was filed by plaintiff on May 29, 2019. Dkt. 1. This 26 court’s April 6, 2020 order contains a more thorough recitation of the underlying factual 27 background of this case. See Dkt. 63. To briefly summarize, this case involves the 1 (defendants) to Henry Schein Animal Health and Butler Animal Health Supply, LLC 2 (“Schein”), products that were ruined en route to Schein. See id. at 2. Plaintiff is a group 3 of insurers that paid out Schein’s insurance claim and now asserts that party’s claims. 4 TCSL, Inc.1 (“TCSL”) was the carrier of the shipment in question and CHR was alleged to 5 have issued the bill of lading and coordinated communication between TCSL and Schein. 6 Id. 7 The relevant procedural history is as follows. On June 26, 2019, plaintiff filed a 8 first amended complaint (Dkt. 16), to which defendants Abaxis and Zoetis filed a motion 9 to dismiss (Dkt. 20). Upon the parties’ stipulation, plaintiff filed the operative Second 10 Amended Complaint (“SAC”) and defendants agreed to refile their motion to dismiss. 11 The SAC dismissed two of three claims alleged against Abaxis and Zoetis, leaving only a 12 breach of contract claim pled against them. Dkt. 28. On September 23, 2019, plaintiff 13 voluntarily dismissed all claims against TCSL. (Dkt. 35), and on October 17, 2019, 14 plaintiff voluntarily dismissed all claims against CHR pursuant to a settlement agreement, 15 (Dkt. 38). 16 On November 20, 2019, this court denied defendants Abaxis and Zoetis’s motion 17 to dismiss (Dkt. 40), and then on December 4, 2019, defendants filed an answer to the 18 SAC and crossclaims (“Crossclaim”) against TCSL and CHR (Dkt. 42). The Crossclaim 19 against CHR incorporated by reference the allegations in the SAC and further alleged 20 that TCSL, acting at the direction of or in conjunction with CHR, negligently mishandled 21 the shipment of pharmaceuticals obtained from Abaxis. Crossclaim ¶ 20. In response to 22 defendants’ Crossclaim, CHR filed a Rule 12(b)(6) motion to dismiss. Dkt. 42. On April 23 6, 2020, this court granted CHR’s motion and granted leave to amend the crossclaim 24 within twenty-one days. Dkt. 63. 25 On April 27, 2020, defendants Abaxis and Zoetis filed their First Amended Answer 26 and Crossclaim (“FACC,” Dkt. 66) as well as the present motion requesting leave to file a 27 1 proposed Second Amended Answer & Crossclaim (“SACC,” Dkt. 67-2) against cross- 2 defendants, CHR and TCSL. Mtn. at 1. Defendants seek leave to file new crossclaims 3 for negligence, negligent misrepresentation, conversion, and negligent interference with 4 economic advantage, as well as their previously asserted crossclaims for equitable 5 indemnification, and contribution. Id. at 4. 6 While the parties were briefing the motion for leave to amend, CHR filed a motion 7 to dismiss the FACC on May 11, 2020. Dkt. 68. On May 26, 2020, defendants filed an 8 opposition to CHR’s motion to dismiss. Dkt. 74. While not directly involved in the 9 crossclaim or the motion to dismiss, the opposition contained statements that caused 10 plaintiff to file a motion seeking to address purportedly frivolous allegations in defendants’ 11 opposition brief. Dkt. 75. 13 A. Legal Standard 14 Federal Rule of Civil Procedure 15 requires that a plaintiff obtain either consent of 15 the defendant or leave of court to amend its complaint once the defendant has answered, 16 but “leave shall be freely given when justice so requires.” Fed. R. Civ. P. 15(a); see, e.g., 17 Chodos v. W. Publ’g Co., 292 F.3d 992, 1003 (9th Cir. 2002) (leave to amend granted 18 with “extreme liberality”). Leave to amend is thus ordinarily granted unless the 19 amendment is futile, would cause undue prejudice to the defendants, or is sought by 20 plaintiffs in bad faith or with a dilatory motive. Foman v. Davis, 371 U.S. 178, 182 (1962); 21 Smith v. Pac. Properties & Dev. Corp., 358 F.3d 1097, 1101 (9th Cir. 2004). While courts 22 should consider all such factors, “the crucial factor is the resulting prejudice to the 23 opposing party.” Howey v. United States, 481 F.2d 1187, 1190 (9th Cir. 1973). 24 B. Analysis 25 1. Summary of Defendants’ Proposed Second Amended Answer & 26 Crossclaim 27 While the FACC only brings two claims against TCSL and CHR for indemnification 1 and CHR: (1) negligence; (2) negligent misrepresentation; (3) conversion; (4) negligent 2 interference with economic advantage; (5) equitable indemnification; and (6) contribution. 3 Dkt. 67-2. Because only CHR opposes the motion to amend, the court briefly describes 4 the proposed crossclaims asserted against CHR. 5 Defendants’ first crossclaim for negligence alleges that CHR breached its duty of 6 care when TCSL, acting at the direction of CHR, took goods from defendants it did not 7 have a right to receive or transport. Id. ¶¶ 29–41.2 Defendants’ second crossclaim for 8 conversion alleges that TCSL acted on behalf of CHR when it mishandled the shipment 9 at issue, which caused permanent damage to its contents. Id. ¶¶ 42–48. Defendants’ 10 third crossclaim for negligent misrepresentation alleges that a TCSL employee, who was 11 dispatched at the direction of CHR, orally represented that he was authorized to receive 12 and transport the pharmaceutical products at issue, even though the employee knew he 13 did not have the power to do so. Id. ¶¶ 49–59. Defendants’ fourth crossclaim for 14 negligent interference with prospective economic advantage alleges that the negligent 15 conduct carried out at the direction of CHR prevented defendants from realizing the 16 economic benefits of their contractual relationship with Schein. Id. ¶¶ 60–70. 17 Defendants also re-allege their crossclaims for equitable indemnification and 18 contribution. Id. ¶¶ 71–80. 19 2. Whether Defendants’ Amendment Meets the Requirements of Rule 15 20 Under Rule 15, “[t]he court should freely give leave [to amend the complaint] when 21 justice so requires.” Fed. R. Civ. P. 15(a)(2). This policy is “to be applied with extreme 22 liberality.” Eminence Capital, LLC v. Aspeon, Inc., 316 F.3d 1048, 1051–52 (9th Cir. 23 2003).
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 3
SUBSCRIBING TO COVER NOTE Case No. 19-cv-02945-PJH 8 B1526MACAR1800089,
9 Plaintiff, ORDER GRANTING MOTION FOR LEAVE TO AMEND; DENYING 10 v. WITHOUT PREJUDICE MOTION TO DISMISS; AND DENYING MOTION 11 ABAXIS, INC., et al., FOR LEAVE TO RESPOND 12 Defendants. Re: Dkt. Nos. 67, 68, 75
14 15 Before the court is defendants Abaxis, Inc. (“Abaxis”) and Zoetis, Inc.’s (“Zoetis” 16 and together with Abaxis, “defendants”) motion for leave to file a second amended 17 answer and crossclaim. Also before the court are cross-defendant C.H. Robinson 18 Worldwide, Inc.’s (“CHR” or “cross-defendant”) motion to dismiss and plaintiff 19 Underwriters at Lloyd’s Subscribing to Cover Note B1526MACAR1800089’s 20 (“Underwriters” or “plaintiff”) motion for leave to respond. The matters are fully briefed 21 and suitable for decision without oral argument. Having read the parties’ papers and 22 carefully considered their arguments and the relevant legal authority, and good cause 23 appearing, the court hereby rules as follows. 25 The complaint in this action was filed by plaintiff on May 29, 2019. Dkt. 1. This 26 court’s April 6, 2020 order contains a more thorough recitation of the underlying factual 27 background of this case. See Dkt. 63. To briefly summarize, this case involves the 1 (defendants) to Henry Schein Animal Health and Butler Animal Health Supply, LLC 2 (“Schein”), products that were ruined en route to Schein. See id. at 2. Plaintiff is a group 3 of insurers that paid out Schein’s insurance claim and now asserts that party’s claims. 4 TCSL, Inc.1 (“TCSL”) was the carrier of the shipment in question and CHR was alleged to 5 have issued the bill of lading and coordinated communication between TCSL and Schein. 6 Id. 7 The relevant procedural history is as follows. On June 26, 2019, plaintiff filed a 8 first amended complaint (Dkt. 16), to which defendants Abaxis and Zoetis filed a motion 9 to dismiss (Dkt. 20). Upon the parties’ stipulation, plaintiff filed the operative Second 10 Amended Complaint (“SAC”) and defendants agreed to refile their motion to dismiss. 11 The SAC dismissed two of three claims alleged against Abaxis and Zoetis, leaving only a 12 breach of contract claim pled against them. Dkt. 28. On September 23, 2019, plaintiff 13 voluntarily dismissed all claims against TCSL. (Dkt. 35), and on October 17, 2019, 14 plaintiff voluntarily dismissed all claims against CHR pursuant to a settlement agreement, 15 (Dkt. 38). 16 On November 20, 2019, this court denied defendants Abaxis and Zoetis’s motion 17 to dismiss (Dkt. 40), and then on December 4, 2019, defendants filed an answer to the 18 SAC and crossclaims (“Crossclaim”) against TCSL and CHR (Dkt. 42). The Crossclaim 19 against CHR incorporated by reference the allegations in the SAC and further alleged 20 that TCSL, acting at the direction of or in conjunction with CHR, negligently mishandled 21 the shipment of pharmaceuticals obtained from Abaxis. Crossclaim ¶ 20. In response to 22 defendants’ Crossclaim, CHR filed a Rule 12(b)(6) motion to dismiss. Dkt. 42. On April 23 6, 2020, this court granted CHR’s motion and granted leave to amend the crossclaim 24 within twenty-one days. Dkt. 63. 25 On April 27, 2020, defendants Abaxis and Zoetis filed their First Amended Answer 26 and Crossclaim (“FACC,” Dkt. 66) as well as the present motion requesting leave to file a 27 1 proposed Second Amended Answer & Crossclaim (“SACC,” Dkt. 67-2) against cross- 2 defendants, CHR and TCSL. Mtn. at 1. Defendants seek leave to file new crossclaims 3 for negligence, negligent misrepresentation, conversion, and negligent interference with 4 economic advantage, as well as their previously asserted crossclaims for equitable 5 indemnification, and contribution. Id. at 4. 6 While the parties were briefing the motion for leave to amend, CHR filed a motion 7 to dismiss the FACC on May 11, 2020. Dkt. 68. On May 26, 2020, defendants filed an 8 opposition to CHR’s motion to dismiss. Dkt. 74. While not directly involved in the 9 crossclaim or the motion to dismiss, the opposition contained statements that caused 10 plaintiff to file a motion seeking to address purportedly frivolous allegations in defendants’ 11 opposition brief. Dkt. 75. 13 A. Legal Standard 14 Federal Rule of Civil Procedure 15 requires that a plaintiff obtain either consent of 15 the defendant or leave of court to amend its complaint once the defendant has answered, 16 but “leave shall be freely given when justice so requires.” Fed. R. Civ. P. 15(a); see, e.g., 17 Chodos v. W. Publ’g Co., 292 F.3d 992, 1003 (9th Cir. 2002) (leave to amend granted 18 with “extreme liberality”). Leave to amend is thus ordinarily granted unless the 19 amendment is futile, would cause undue prejudice to the defendants, or is sought by 20 plaintiffs in bad faith or with a dilatory motive. Foman v. Davis, 371 U.S. 178, 182 (1962); 21 Smith v. Pac. Properties & Dev. Corp., 358 F.3d 1097, 1101 (9th Cir. 2004). While courts 22 should consider all such factors, “the crucial factor is the resulting prejudice to the 23 opposing party.” Howey v. United States, 481 F.2d 1187, 1190 (9th Cir. 1973). 24 B. Analysis 25 1. Summary of Defendants’ Proposed Second Amended Answer & 26 Crossclaim 27 While the FACC only brings two claims against TCSL and CHR for indemnification 1 and CHR: (1) negligence; (2) negligent misrepresentation; (3) conversion; (4) negligent 2 interference with economic advantage; (5) equitable indemnification; and (6) contribution. 3 Dkt. 67-2. Because only CHR opposes the motion to amend, the court briefly describes 4 the proposed crossclaims asserted against CHR. 5 Defendants’ first crossclaim for negligence alleges that CHR breached its duty of 6 care when TCSL, acting at the direction of CHR, took goods from defendants it did not 7 have a right to receive or transport. Id. ¶¶ 29–41.2 Defendants’ second crossclaim for 8 conversion alleges that TCSL acted on behalf of CHR when it mishandled the shipment 9 at issue, which caused permanent damage to its contents. Id. ¶¶ 42–48. Defendants’ 10 third crossclaim for negligent misrepresentation alleges that a TCSL employee, who was 11 dispatched at the direction of CHR, orally represented that he was authorized to receive 12 and transport the pharmaceutical products at issue, even though the employee knew he 13 did not have the power to do so. Id. ¶¶ 49–59. Defendants’ fourth crossclaim for 14 negligent interference with prospective economic advantage alleges that the negligent 15 conduct carried out at the direction of CHR prevented defendants from realizing the 16 economic benefits of their contractual relationship with Schein. Id. ¶¶ 60–70. 17 Defendants also re-allege their crossclaims for equitable indemnification and 18 contribution. Id. ¶¶ 71–80. 19 2. Whether Defendants’ Amendment Meets the Requirements of Rule 15 20 Under Rule 15, “[t]he court should freely give leave [to amend the complaint] when 21 justice so requires.” Fed. R. Civ. P. 15(a)(2). This policy is “to be applied with extreme 22 liberality.” Eminence Capital, LLC v. Aspeon, Inc., 316 F.3d 1048, 1051–52 (9th Cir. 23 2003). In determining whether to grant leave to amend, the court applies the factors 24 articulated in Foman v. Davis:
26 2 Defendants’ proposed SACC brings claims against both TCSL and CHR; however, defendants separated the claims into, essentially, two separate complaints with the same 27 paragraph numbers. Because only CHR is opposing the motion to amend, the court In the absence of any apparent or declared reason—such as 1 undue delay, bad faith or dilatory motive on the part of the movant, repeated failure to cure deficiencies by amendments 2 previously allowed, undue prejudice to the opposing party by virtue of allowance of the amendment, futility of amendment, 3 etc.—the leave sought should, as the rules require, be “freely given.” 4 5 371 U.S. at 182. 6 Prejudice is the “touchstone of the inquiry under Rule 15(a)” and the “party 7 opposing amendment ‘bears the burden of showing prejudice.’” Eminence Capital, 316 8 F.3d at 1052 (quoting Lone Star Ladies Inv. Club v. Schlotzsky’s Inc., 238 F.3d 363, 368 9 (5th Cir. 2001); and DCD Programs, Ltd. v. Leighton, 833 F.2d 183, 185 (9th Cir. 1987)). 10 “Absent prejudice, or a strong showing of any of the remaining Foman factors, there 11 exists a presumption under Rule 15(a) in favor of granting leave to amend.” Id. (citing 12 Lowrey v. Tex. A & M Univ. Sys., 117 F.3d 242, 245 (5th Cir. 1997)). 13 a. Undue Prejudice 14 Undue prejudice exists “where the ‘parties have engaged in voluminous and 15 protracted discovery’ prior to amendment, or where ‘[e]xpense, delay, and wear and tear 16 on individuals and companies’ is shown.” Utterkar v. Ebix, Inc., No. 14-CV-02250-LHK, 17 2015 WL 5027986, at *6 (N.D. Cal. Aug. 25, 2015) (alteration in original) (quoting Kaplan 18 v. Rose, 49 F.3d 1363, 1370 (9th Cir. 1994), overruled on other grounds by City of 19 Dearborn Heights Act 345 Police & Fire Ret. Sys. v. Align Tech., Inc., 856 F.3d 605, 609 20 (9th Cir. 2017); and citing Jackson v. Bank of Haw., 902 F.2d 1385, 1387–88 (9th Cir. 21 1990)). 22 Defendants contend that there is no undue prejudice to CHR because CHR has 23 ample time to respond to the proposed claims, through investigation and formal 24 discovery. Mtn. at 11. In response, CHR argues that allowing defendants another 25 attempt to address the deficiencies of their causes of action for indemnity and 26 contribution would result in clear prejudice to CHR. Opp. at 12. CHR also contends that 27 the newly proposed independent tort causes of action will cause prejudice in the expense 1 Here, the prejudice to CHR is not undue, as this case is still in the pleading stage 2 and discovery has not yet commenced. Cf. Zivkovic v. S. Cal. Edison Co., 302 F.3d 3 1080, 1087 (9th Cir. 2002) (holding no abuse its discretion where district court denied 4 leave to amend because motion to amend was filed “only several days before the 5 discovery cut-off and less than three months before the trial was to commence”). 6 Further, the present motion is defendants’ first request to amend their complaint to allege 7 independent tort claims and the expense to CHR to file a motion to dismiss is not 8 disproportionate. Thus, the undue prejudice factor weighs in favor of granting the motion 9 and, absent a strong showing of the remaining Foman factors, there is a presumption in 10 favor of granting leave to amend. See Eminence Capital, 316 F.3d at 1052. 11 b. Futility 12 Defendants argue that their proposed claims are not be futile because the claims 13 are based on factual allegations that have not been tested by a motion to dismiss. Mtn. 14 at 9–10. In response, CHR advances several arguments as to why granting leave to 15 amend would be futile, including renewing their arguments pertaining to indemnification 16 and contribution as well as substantive arguments attacking the viability of the new 17 claims. See Opp. at 6–12. 18 Generally, CHR’s futility argument seeks to challenge whether the SACC states a 19 claim. Whatever the ultimate conclusion on the viability of defendants’ claims, CHR’s 20 arguments are better tested at the motion to dismiss stage, rather than through a motion 21 to amend. See Bd. of Trustees of the Auto. Indus. Welfare Fund v. Groth 22 Oldsmobile/Chevrolet, Inc., No. C 09-0465 PJH, 2010 WL 760452, at *3 (N.D. Cal. Mar. 23 4, 2010) (“This court normally will not rule on the futility of an amendment at the motion to 24 amend stage of the litigation unless the proposed amendment is clearly and 25 unambiguously futile.”). The court previously dismissed defendants’ indemnification and 26 contribution claims without prejudice and defendants’ newly proposed tort claims have 27 not been tested by a motion to dismiss. Given the procedural posture, it is premature to 1 weighs in favor of granting leave to amend. 2 The court acknowledges that CHR’s pending motion to dismiss will be mooted by 3 the filing of the proposed SACC and that CHR has reserved the right to file a renewed 4 motion to dismiss. Mtn. at 12. The court will permit CHR the opportunity to file a 5 renewed motion to dismiss, which will also mitigate any prejudice to CHR. 6 c. Bad Faith or Dilatory Motive 7 Generally, an “amendment should be permitted unless it will not save the 8 complaint or the plaintiff merely is seeking to prolong the litigation by adding new, but 9 baseless legal theories.” Griggs v. Pace Am. Grp., Inc., 170 F.3d 877, 881 (9th Cir. 10 1999) (citing Steckman v. Hart Brewing, Inc., 143 F.3d 1293, 1296 (9th Cir. 1998)). 11 In their motion, defendants argue there is no bad faith because they have been 12 diligent in their attempts to plead these crossclaims, first as equitable indemnity and 13 contribution and now as independent claims once the court issued its April 6th order 14 dismissing the original equitable indemnity and contribution claims. Mtn. at 8. In 15 response, CHR argues that the only way defendants can successfully hold CHR 16 responsible is through an indemnity and contribution claim, both of which were dismissed 17 in a prior order. Opp. at 5. CHR contends, therefore, that defendants’ motive is dilatory 18 because the independent tort claims cannot be asserted to hold CHR liable. Id. 19 CHR’s argument as to dilatory motive depends on the outcome of a future Rule 20 12(b)(6) claim that tests the viability of defendants’ proposed crossclaims. Without 21 presupposing the outcome of such a motion to dismiss, it is not clear that defendants’ 22 motive is dilatory. While the court previously dismissed defendants’ equitable indemnity 23 and contribution claims, it acknowledged that defendants might be able to allege new 24 factual matter to overcome the deficiencies identified in the order. Thus, it is not clear 25 that defendants seek to prolong the litigation by adding new, baseless legal theories. 26 Accordingly, CHR has not demonstrated bad faith or dilatory motive shown on the part of 27 defendants. 1 d. Undue Delay 2 Delay, by itself, is insufficient to justify denial of leave to amend. DCD Programs, 3 Ltd., 833 F.2d at 183–86; see also Hurn v. Ret. Fund Tr. of Plumbing, Heating & Piping 4 Indus. of S. Cal., 648 F.2d 1252, 1254 (9th Cir. 1981). Instead, “[c]ourts previously have 5 found that a party unduly delayed when the party sought to amend a pleading with 6 previously-known facts, particularly when the delay is accompanied by the requisite 7 showing of other Foman factors such as prejudice.” Uttekar, 2015 WL 5027986, at *7. 8 Defendants argue that they sought to amend their crossclaim soon after the 9 court’s April 6th order that dismissed without prejudice their crossclaims for indemnity 10 and contribution, and thus, they did not cause undue delay. Mtn. at 9. In response, CHR 11 argues that defendants should have filed these claims when they first answered the SAC 12 in December 2019. Opp. at 6. CHR further contends that the proposed SACC is a last 13 ditch attempt to accomplish what the failed causes of action for indemnity and 14 contribution could not accomplish from the original answer and crossclaim. Id. 15 Both defendants and cross-defendant raise valid points as to delay. On the one 16 hand, defendants are seeking leave to amend within a few weeks of their original 17 Crossclaim being dismissed without prejudice and within the timeframe for which the 18 court permitted amendment. See Dkt. 63 at 9. On the other hand, cross-defendant 19 raises a point that defendants were aware of the underlying facts in this case and 20 neglected to allege independent tort claims until now. However, this delay is not undue 21 because this case is still in the pleading stage and the parties have not completed 22 discovery. Moreover, the other Foman factors weigh in favor of granting leave to amend. 23 Thus, CHR has not established undue delay in this case and granting leave to amend is 24 warranted. 25 3. Disposition of Remaining Motions 26 On May 11, 2020, CHR filed a motion to dismiss the first amended crossclaim. 27 Dkt. 68. Because the court grants defendants’ leave to amend, CHR’s pending motion 1 defendants file their proposed SACC. 2 Next, defendants filed an opposition to CHR’s motion on May 26, 2020. Dkt. 74. 3 In response to certain statements in the opposition, plaintiff filed a motion for leave to 4 respond to frivolous allegations. Dkt. 75. In the opposition brief, defendants state that 5 plaintiff “simply dropped the cause of action for negligence against Abaxis and Zoetis on 6 the understanding that doing so would preclude Abaxis and Zoetis from recovering in 7 equitable indemnity . . . .” Dkt. 74 at 13. Defendants also contend that plaintiff and CHR 8 failed to a good faith determination from the court regarding the settlement between 9 those two parties. Id. at 12–13. Defendants also alleges that plaintiff and CHR’s conduct 10 “raises genuine concerns of collusion.” Id. at 14. 11 In response, plaintiff contends that defendants sought the negligence claims 12 against them to be dismissed, through the filing of a prior motion to dismiss and 13 associated communications. Dkt. 75 at 4. With regard to the good faith settlement 14 determination, plaintiff contends that its only claim against CHR sounded in federal law 15 and the good faith settlement determination, which is required under California law, is 16 inapplicable. Id. at 6. Plaintiff also contends that defendants’ references to collusion are 17 unprofessional and unsubstantiated. Id. at 8. 18 The court understands plaintiff’s motion as only a request to submit the 19 memorandum of points and authorities in response to defendants’ opposition to CHR’s 20 motion to dismiss because it is not directly involved in CHR’s motion to dismiss. Dkt. 75 21 at 2. Because the underlying motion to dismiss is being denied without prejudice, 22 defendants’ opposition is, therefore, moot. For that reason, plaintiff’s motion is 23 essentially mooted and will be denied on that ground alone. The court is cognizant, 24 however, of the issues raised in plaintiff’s motion, especially concerning defendants’ 25 accusation of collusion between plaintiff and CHR. Accordingly, all parties are warned 26 that all future filings must adhere to Rule 11’s requirement for attorneys to certify that 27 they have read any pleadings or motions they file with the court and that such pleadings 1 an improper purpose. Fed. R. Civ. P. 11(b). 3 For the foregoing reasons, defendants’ motion to amend is GRANTED. 4 Additionally, cross-defendant’s motion to dismiss is DENIED WITHOUT PREJUDICE and 5 plaintiff’s motion for leave to respond is DENIED. Defendants shall file their proposed 6 second amended answer and crossclaim within 7 days of the filing of this order. Cross- 7 defendant may file a renewed motion or responsive pleading within 21 days of the filing of 8 the second amended answer and crossclaim. 10 Dated: June 15, 2020 11 /s/ Phyllis J. Hamilton PHYLLIS J. HAMILTON 12 United States District Judge 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27